In the study presented here, a new series of 2-furyl(4-{4-[(substituted)sulfonyl]benzyl}-1-piperazinyl) methanone derivatives was targeted. The synthesis was initiated by the treatment of different secondary amines (1a-h) with 4-bromomethylbenzenesulfonyl chloride (2) to obtain various 1-{[4-(bromomethyl) phenyl]sulfonyl}amines (3a-h). 2-Furyl(1-piperazinyl)methanone (2-furoyl-1-piperazine; 4) was then dissolved in acetonitrile, with the addition of K 2 CO 3 , and the mixture was refluxed for activation. This activated molecule was further treated with equi-molar amounts of 3a-h to form targeted 2-furyl(4-{4-[(substituted)sulfonyl]benzyl}-1-piperazinyl)methanone derivatives (5a-h) in the same reaction set up. The structure confirmation of all the synthesized compounds was carried out by EI-MS, IR and 1 H-NMR spectral analysis. The compounds showed good enzyme inhibitory activity. Compound 5h showed excellent inhibitory effect against acetyl-and butyrylcholinesterase with respective IC 50 values of 2.91±0.001 and 4.35±0.004 μM, compared to eserine, a reference standard with IC 50 values of 0.04±0.0001 and 0.85±0.001 μM, respectively, against these enzymes. All synthesized molecules were active against almost all Gram-positive and Gram-negative bacterial strains tested. The cytotoxicity of the molecules was also checked to determine their utility as possible therapeutic agents.
INTRODUCTION
Sulfonamides have received a lot of attention in the literature because of their exciting biological properties and their role as pharmacophores of considerable historical importance (Abbasi et al., 2016a, b) . Heterocyclic sulfonamides have been found to be carbonic anhydrase inhibitors (Surpuran et al., 1998; Di Fiore et al., 2010; Smaine et al., 2008) and antibacterial (Gadad et al., 2000) and anticancer, antiinflammatory and analgesic (Sondhi et al., 2000) agents. Furthermore, the piperazine core has displayed a wide spectrum of pharmacological activities and is part of a number of drugs that are preclinical and clinical candidates (Welsch, Snyder, Stockwell, 2010; Hussain et al., 2016) .
Cholinesterases (acetylcholinesterase, AChE (EC 3.1.1.7)), butyrylcholinesterase, BChE (EC 3.1.1.8)), belong to the class of serine hydrolases and are responsible for the inactivation of acetylcholine at cholinergic synapses. The main effect of AChE and BChE is to catalyze the hydrolysis of the neurotransmitter acetylcholine and termination of the nerve impulse at cholinergic synapses Page 2 / 11 (Cygler et al., 1993) . BChE is extensively present in Alzheimer's plaques (Gauthier, 2001) . Cholinesterases play an important role in Alzheimer's disease, and so their inhibitors are of great importance for the treatment of such diseases.
The bioactivity of piperazine and sulfamoyl moieties prompted us to synthesize some new molecules bearing these moieties together. The compounds synthesized were screened to explore their enzyme inhibitory and antibacterial potential. Moreover, we also carried out cytotoxicity and molecular docking studies to determine their utility as possible therapeutic agents in drug development programs.
MATERIAL AND METHODS

General
Chemicals were purchased from Sigma Aldrich and Alfa Aesar (Germany), and solvents of analytical grade were from local suppliers. Melting points were taken uncorrected on a Griffin and George apparatus using the open capillary tube method. Thin layer chromatography (TLC) using ethylacetate:n-hexane (30:70) as mobile phase, with detection at 254 nm, was used to determine the initial purity of the compounds. IR spectra were recorded on a Jasco-320-A spectrometer by using the KBr pellet method.
1 H-NMR spectra were recorded at 500 MHz in CDCl 3 using a Bruker spectrometer. EIMS spectra were recorded with a JMS-HX-110 spectrometer.
Synthesis of 1-{[4-(bromomethyl)phenyl]sulfonyl} amines (3a-h)
Different secondary amines (1a-h; 15.0 mmol) were suspended in 15 mL of distilled water in an iodine flask. The pH was adjusted to 9-10 with 10% Na 2 CO 3 , and 4-bromomethylbenzenesulfonyl chloride (2; 15.0 mmol) was added dropwise to the reaction mixture in 2-5 min. After complete addition, the iodine flask was vigorously shaken (manually) until the formation of solid precipitates. The progress of the reaction was monitored by TLC. The solid obtained was filtered, washed with distilled water and dried to yield the corresponding electrophiles 1-{[4-(bromomethyl)phenyl]sulfonyl}amines 3a-h.
Synthesis of 2-furyl(4-{4-[(substituted)sulfonyl] benzyl}-1-piperazinyl)methanone derivatives (5a-h)
2-Furyl(1-piperazinyl)methanone (2-furoyl-1-piperazine; 4; 0.1 g, 0.0045 mol) was dissolved in acetonitrile (20-30 mL) in a 100-mL round-bottom flask. Solid K 2 CO 3 (0.0135 mol) was added and the mixture was refluxed for 0.5 h to activate compound 4. The desired electrophiles 1-{[4-(bromomethyl)phenyl] sulfonyl}amines 3a-h, 0.0045 mol, were added separately in each reaction. The mixture was refluxed for 4-5 h for completion. TLC was carried out to check reaction completion. Distilled water was added to the reaction mixture to obtain the precipitates, which were filtered, washed and dried to yield the desired products 2-furyl(4-{4-[(substituted)sulfonyl]benzyl}-1-piperazinyl) methanone derivatives 5a-h. (4-{4-[(3,5-dimethyl-4-morpholinyl) 
2-Furyl(4-{4-[(3-methyl-1-piperidinyl)sulfonyl] benzyl}-1-piperazinyl)methanone (5e)
Brown amorphous solid; Yield: 80%; m. 
2-
Biological activity assays
Cholinesterase assays
The AChE and BChE inhibition study was performed according to an established method (Ellman et al., 1961) . The percent inhibition was calculated by the following equation:
The IC 50 (concentration at which there is 50% enzyme inhibition) of compounds was calculated using EZ-Fit Enzyme Kinetics Software (Perrella Scientific Inc. Amherst, USA).
Antibacterial activity
The antibacterial activity test was performed in sterile 96-wells microplates under aseptic environments. The method is rooted in the principle that microbial cell number increases as the microbial growth proceeds in a log phase of growth, which results in increased absorbance of broth medium (Kaspady et al., 2009; Yang et al., 2006) . Three Gram-negative (Salmonella typhi, Escherichia coli and Pseudomonas aeruginosa) and two Gram-positive bacteria (Bacillus subtilis, Staphylococcus aureus) were included in the study. The organisms were maintained on stock culture agar medium. The test samples with suitable solvents and dilutions were pipette into wells (20 µg/well). Overnight maintained fresh bacterial culture after suitable dilution with fresh nutrient broth was poured into wells (180 µL). The initial absorbance of the culture was strictly maintained between 0.12-0.19 at 540 nm. The total volume in each well was kept to 200 µL. The incubation was done at 37 o C for 16-24 hours with lid on the microplate. The absorbance was measured, before and after incubation and the difference was noted as an index of bacterial growth at 540 nm by using microplate reader. The percent inhibition was calculated by using the formula:
where X is absorbance in control with bacterial culture and Y is absorbance in test sample. Results are mean of triplicate (n=3, ± SEM). Ciprofloxacin was taken as standard.
Statistical analysis
The results are written as mean ± SEM after performance in three-folds and statistical analysis by Microsoft Excel 2010. Minimum inhibitory concentration (MIC) was calculated by using different dilutions (ranging 5-30 μg/well) and EZFit Perrella Scientific Inc. Amherst USA software.
Hemolytic activity
Hemolytic activity was evaluated by a previously reported method (Sharma, Sharma, 2001; Powell, Catranis, Maynard, 2000) . Human blood was obtained from volunteers according to the Department of Clinical Medicine and Surgery, University of Agriculture, Faisalabad, Pakistan. After centrifugation, separation and washing, the % RBCs lysis was computed by noting the absorbance.
Molecular docking
To predict the bioactive conformations, various compounds (ligands) were docked into the binding pockets of the selected proteins (enzymes) by using the default parameters of MOE-Dock program.
Ligand preparation
The three-dimensional (3D) structures of the compounds synthesized were modeled by using the Build program of MOE 2009-10. The energies of the compounds were then minimized by using the default parameter of MOE energy minimization algorithm (gradients: 0.05, force field: MMFF94X). Database was created in which all the compounds (3D structures) were saved in the mdb file format for the next step of docking.
Receptor protein preparation
The 3D structures of receptor protein molecules of AChE (PDB ID code: 1Zi3; Resolution: 1.69Å) and BChE (PDB ID code: 1POP; Resolution: 2.30Å) were downloaded from Protein Data Bank. All water molecules were removed from the receptor proteins and 3D protonation was carried out by using Protonate 3D Option. Protein molecules were energy minimized by using the default parameters of MOE 2009-10 energy minimization algorithm (gradient: 0.05, Force Field: MMFF94X). By using default parameters of MOE-Dock Program, all the ligands were docked into binding sites of the above proteins. Re-docking procedure was also used to increase the validity of docking protocol (Bostro, Greenwood, Gottfries, 2003) .
RESULTS AND DISCUSSION
The purpose of the present study was to synthesize new molecules and to evaluate their biological activities against different enzymes and various bacterial strains. In addition, the cytotoxicity of the new compounds was also evaluated. Different 2-furyl(4-{4-[(substituted) sulfonyl]benzyl}-1-piperazinyl)methanone derivatives (5a-h) were synthesized in various steps as described in Scheme 1. The synthesis was carried out by the treatment of different secondary amines (1a-h) with 4-bromomethylbenzenesulfonyl chloride (2) to obtain solid electrophiles, 3a-h, which were collected through filtration. 2-Furyl(1-piperazinyl)methanone (2-furoyl-1-piperazine; 4) was then dissolved in acetonitrile and K 2 CO 3 added, and the mixture was refluxed for 0.5 h for activation of this molecule. This solution was mixed with an equimolar amount of 1-{[4-(bromomethyl)phenyl] sulfonyl}amines (3a-h), to form the target 2-furyl(4-{4-[(substituted)sulfonyl]benzyl}-1-piperazinyl)methanones (5a-h).
Chemistry
The structural analysis of one of the compounds is discussed here in detail for the benefit of the reader. Compound 5c was synthesized as a light brown crystalline solid with a melting point of 60-62 o C and molecular formula of C 21 H 27 N 3 O 4 S, which was confirmed by EI-MS with a [M] + peak of 417. The distinct peak at m/z 95 was related to the furan-2-carbaldehyde part of the molecule. The fragmentation pattern of this molecule is outlined in Figure 1 . In the IR spectrum, characteristic peaks appeared at 3086 (C-H stretch of aromatic ring), 2878 (C-H stretch of aliphatic), 1659 (C=O stretch), 1576 (C=C aromatic stretch), 1426 (S=O), 1191 (C-O-C bond stretch) and 1109 (C-N-C bond stretch), confirming the presence of sulfonamide and 2-furoyl-1-piperazine ring.
In 1 H-NMR spectrum, two signals of aromatic protons appeared at δ 7.68 (d, J = 8.2 Hz, 2H, H-3'' & H-5''), 7.47 (d, J = 8.1 Hz, 2H, H-2'' & H-6''), which were typical for 1,4-disubstituted aromatic ring. The furan ring showed three peaks in the aromatic region at δ 7.50-7.47 (merged s, 1H, H-5'), 6.97 (d, J = 3.3 Hz, 1H, H-3') and 6.47 (dd, J = 1.7, 3.3 Hz, 1H, H-4'). In the aliphatic region, signals appeared for a piperazine ring at δ 3.76 (br.s, 4H, CH 2 -2 & CH 2 -6) and 2.98 (m, 4H, CH 2 -3 & CH 2 -5) for piperazine ring at δ 3.52 (s, 2H, CH 2 -7'') and signals for a piperidine ring at δ 2.92 (m, 4H, CH 2 -2''' & CH 2 -6'''), 1.59 (m, 4H, CH 2 -3''' & CH 2 -5''') and 1.50 (m, 2H, CH 2 -4''') with attached sulfonamide group. The EIMS and 1 H-NMR spectra of this molecule are shown in Figure 2 and Figure 3 , respectively. These spectral data confirmed thev structure of this molecule as 2-furyl{4- [4-(1-piperidinylsulfonyl) benzyl]-1-piperazinyl}methanone. Similarly, the structures of all the synthesized molecules, SCHEME 1 -Outline for the synthesis of 2-Furyl(4-{4-[(substituted)sulfonyl]benzyl}-1-piperazinyl)methanone derivatives (5a-h). Reagents and conditions: (I) 10% Na 2 CO 3 , pH 9-10, Stirring at room temperature for 3-4 hours; (II) Acetonitrile, K 2 CO 3 , reflux for 0.5 hours (III) Reflux for 4-5 hours after addition of electrophiles, 3a-h, separately one by one in each reaction. 5a-h, were characterized by their IR, 1 H-NMR and EI-MS spectral analysis.
Biological activities
Cholinesterase assays
The results of screening the compounds against cholinesterase are given as % inhibition and IC 50 in Table I .
Against AChE, (4-{4-[(3,5-dimethyl-1-piperidinyl) sulfonyl]benzyl}-1-piperazinyl)(2-furyl)methanone (5h) was found to be an excellent inhibitor with an IC 50 of 2.91 ± 0.001 μM, compared to eserine, a reference standard with an IC 50 of 0.04 ± 0.0001 μM, probably due to the presence of the 3,5-dimethyl-1-piperidinyl group. Among the other molecules, 2-furyl(4-{4-[(4-methyl-1-piperidinyl)sulfonyl]benzyl}-1-piperazinyl)methanone (5f) and 2-furyl(4-{4-[(2-methyl-1-piperidinyl)sulfonyl] benzyl}-1-piperazinyl)methanone (5d), with IC 50 values of 13.72 ± 0.06 and 33.42 ± 0.05 μM, respectively, were found to be excellent inhibitors probably due to the presence of 4-methyl-1-piperidinyl and 2-methyl-1-piperidinyl groups.
With regard to BChE, 4-{4-[(3,5-dimethyl-1-piperidinyl)sulfonyl]benzyl}-1-piperazinyl)(2-Furyl) methanone (5h) and 2furyl(4-{4-[(3-methyl-1-piperidinyl)sulfonyl]benzyl}-1-piperazinyl)methanone (5e) both showed very comparable inhibitory potential compared to the standard used against, as evident from their IC 50 values. The results are given in Table I . The IC 50 values of these compounds were calculated to be 4.35 ± 0.004 and 8.33 ± 0.007 μM, respectively, compared to eserine with an IC 50 of 0.85 ± 0.001 μM. The significant inhibitory potential of these molecules could have been attributed to the substitution of 3,5-dimethyl-1-piperidinyl and 3-methyl-1-piperidinyl groups. In the future these molecules can be further investigated to introduce new drug candidates.
Antibacterial activity (in vitro)
All the compounds synthesized were screened against various Gram-positive and Gram-negative bacterial strains, and most of them were found to be potent inhibitors. The results are tabulated as % inhibition and MIC values in Tables II and III, respectively. Against S. typhi, 2-furyl(4-{4-[(3-methyl-1- (4-{4-[(3,5-dimethyl-4-morpholinyl) sulfonyl]benzyl}-1-piperazinyl)(2-furyl)methanone (5b) showed the lowest MIC value of 9.25 ± 0.18 μM, presumably owing to the presence of the 3,5-dimethyl-4-morpholinyl group. Surprisingly, all molecules tested were inactive against S. aureus.
Hemolytic activity
The highest hemolytic activity was shown by 5g (35.98%), higher than the positive control (Triton X-100). The lowest activity was shown by 5e (1.66%) but higher than the negative control (PBS), as shown in Table I . Some of these molecules might be further tested for their application in drug designing programs because of moderate toxicity.
Computational Docking
It is clear from Figure 2 (2D and 3D) that compound 5h was deeply bound in the binding pockets of AChE by making two important interactions with the amino acid residues Asp211 and Trp300. Asp211 interacted strongly with the nitrogen of the piperazine ring of the ligand through Mn ++ , giving a bond length of 2.19 Å. A second arene-arene interaction was made between Trp300 and furyl rings with a bond distance of 3.60 Å. Val210, Asp302, Glu303 and Phe121 were also present in the nearby vicinity.
Similarly, molecule 5f showed two interactions with this enzyme. Lys125 interacted strongly with the sulfonyl oxygen of the ligand through side chain donor interaction. The bond length calculated was 2.57 Å. Tyr126 made an arene-arene interaction with the benzyl ring of the compound, giving a bond distance of 3.77 Å, as shown in Figure 3 (2D and 3D) .
The in silico study with butyrylcholinesterase (BChE) revealed that 5h also and another compound, 5e, exhibited considerable interaction. It was inferred that F I G U R E 2 -The 2D and 3D interaction analysis of 4-{4-[(3,5-dimethyl-1-piperidinyl)sulfonyl]benzyl}-1-piperazinyl)(2-furyl)methanone (5h) with acetylcholinesterase.
FIGURE 3 -The 2D and 3D interaction analysis of 2-furyl(4-{4-[(4-methyl-1-piperidinyl)sulfonyl]benzyl}-1-piperazinyl) methanone (5f) with acetylcholinesterase. 5h exhibited two interactions. The first side chain donor interaction was between Thr120 and the sulfonyl oxygen with a distance of 3.53 Å, while the second arene-cation interaction was between His438 and the furoyl ring of the ligand with a bond length of 3.8 9Å (Figure 4; 2D and 3D ).
In the same way, compound 5e had two interactions with the active site residues Thr120 and Trp82. Thr120 had a strong side chain donor interaction with the sulfonyl oxygen, showing a bond distance of 3.56 Å, but Trp82 produced an arene-arene interaction with the furoyl ring, showing a bond length of 4.06Å ( Figure 5; 2D and 3D ). Met437, Gly116 and His438 were also present very close to the ligand.
CONCLUSION
The synthesized compounds were confirmed by spectral data. It was evident from enzyme inhibition analysis that compound 5h exhibited potent inhibitory activity against AChE and BChE, with IC 50 of 2.91 ± 0.001 and 4.35±0.004 μM, respectively, as compared to the standard eserine, with IC 50 of 0.04 ± 0.0001 and 0.85 ± 0.001 μM, which could be attributed to the presence of the 3,5-dimethyl-1-piperidinyl group in this molecule. These results were fully supported by their in silico study. Putting S. aureus aside, all of the synthesized molecules were active against the Gram-positive and Gram-negative bacterial strains tested, except compound 5e, which was inactive against P. aeroginosa. The hemolytic study was also carried out to evaluate the cytotoxicity profile of the synthesized molecules. It was inferred from the results that most of molecules were moderately toxic. Hence, these molecules could be recommended as suitable therapeutic entrants in a drug development program for the pharmaceutical industry.
F I G U R E 4 -T h e 2 D a n d 3 D i n t e r a c t i o n a n a l y s i s o f 4 -{ 4 -[ ( 3 , 5 -d i m e t h y l -1 -p i p e r i d i n y l ) s u l f o n y l ] benzyl}-1-piperazinyl)(2-furyl)methanone (5h) against butrylcholinesterase.
FIGURE 5 -The 2D and 3D interaction analysis of 2-furyl(4-{4-[(3-methyl-1-piperidinyl)sulfonyl]benzyl}-1-piperazinyl) methanone (5e) with butrylcholinesterase.
Page 10 / 11 FIGURE 6 -EIMS spectrum of 2-furyl{4-[4-(1-piperidinylsulfonyl)benzyl]-1-piperazinyl}methanone (5c). 
